Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.4652W HIGH $31.04
Volume
139.67 K
Value Traded
4.44 M
Short % Float
12.71%
+2.5%Week
+0.28%1 Month
+3.84%3 Month
+32.3%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
587.18 M
EPS (TTM)
-3.07
P/E Ratio
-
Ent. Value
35.83 M
Total Shares
27.52 M
Float Shares
17.61 M
Insiders
36.00%
Institutions
57.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FLGT Catalyst Timeline
Dated clinical, regulatory and corporate events for Fulgent Genetics, Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How FLGT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Fulgent Genetics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every FLGT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FID-007 | recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 | 2026-06-01 | objective response rate: 61.9%; median progression free survival: 6.7 months; median duration of response: 7.4 months; one year overall survival: 63.4%Read More | Fulgent Presents Updated FID-007 Data at ASCO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gao HanlinOfficer (Chief Scientific Officer) | Sell | -1,673 986,117 held | $19.66 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FLGT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.2 % | 20.50 M | 1.29 M | 82.83% ( 583.97 K) |
FLGT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FLGT ranks across every disease it competes in
Competitive Position is a premium feature
See how FLGT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFLGT News
-FLGT
Oct 15, 2026▲ +1.6%today
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Fulgent Genetics, Inc. will announce its third quarter 2026 financial results on November 5, 2026, after market close. A conference call will follow at 4:30 PM ET to discuss the results and address questions from the investment community. This reflects the company's commitment to transparency with stakeholders.
Read more →-FLGT
Jul 30, 2026▼ -18.1%on this news
Fulgent Reports Second Quarter 2026 Financial Results
Fulgent Genetics, Inc. reported its financial results for the second quarter of 2026, revealing significant losses. The company experienced a GAAP loss of $29.5 million and a non-GAAP loss of $16.2 million. Adjusted EBITDA also showed a loss of $17.1 million, highlighting ongoing financial difficulties.
Read more →-FLGT
Jul 9, 2026Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Fulgent Genetics, Inc. will announce its second quarter 2026 financial results on July 30, 2026, after market close. A conference call will follow at 4:30 PM ET to discuss the results. The company is transitioning from diagnostics to a comprehensive precision medicine approach, focusing on cancer treatment.
Read more →-FLGT
Jun 1, 2026Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent presented updated data on FID-007 at the ASCO 2026 conference. The details of the data and its implications were not disclosed in the article. The presentation aimed to inform stakeholders about the progress of FID-007 in clinical settings.
Read more →-FLGT
May 21, 2026▲ +5.9%on this news
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent has announced the rapid oral full abstract publication for FID-007, which will be presented within the Head and Neck Cancer track session at the ASCO 2026 Annual Meeting. This event highlights the company's ongoing research efforts in oncology. Further details about the findings and implications of FID-007 are anticipated during the meeting.
Read more →-FLGT
May 1, 2026▼ -7%on this news
Fulgent Reports First Quarter 2026 Financial Results
Fulgent Genetics reported its first quarter 2026 financial results, revealing a revenue of $71.1 million but a GAAP loss of $24.8 million. The company is optimistic about its laboratory services and therapeutic development pipeline, particularly with the upcoming presentation of Phase 2 data for FID-007 at the 2026 ASCO Annual Meeting. Despite the losses, Fulgent maintains its revenue guidance for the year and anticipates improvements in gross margins.
Read more →-FLGT
Apr 22, 2026Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Fulgent has been chosen to present a rapid oral abstract during the Head and Neck Cancer track at the 2026 ASCO Annual Meeting. This opportunity highlights the company's involvement in significant oncology discussions. The details of the abstract and its implications for the field will be revealed at the event.
Read more →-FLGT
Apr 17, 2026Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
Fulgent Genetics, Inc. will announce its first quarter 2026 financial results on May 1, 2026. The company will host a conference call at 8:30 AM ET to discuss the results and engage with the investment community. Fulgent is focused on transitioning from a diagnostic business to a fully integrated precision medicine company.
Read more →-FLGT
Apr 16, 2026Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
Fulgent Genetics is set to announce its financial results for the first quarter of 2026 on May 1, 2026. The announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be provided at the time of the announcement.
Read more →-FLGT
Mar 18, 2026Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million. This acquisition is expected to enhance Fulgent's laboratory services and therapeutic development capabilities. The company aims to transition into a fully integrated precision medicine entity, leveraging the expertise of the acquired laboratories.
Read more →-FLGT
Feb 27, 2026▼ -38.1%on this news
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
Fulgent Genetics reported its financial results for Q4 and full year 2025, highlighting growth in its laboratory services and advancements in its therapeutic pipeline. CEO Ming Hsieh expressed optimism about ongoing strategic investments and product innovation. However, CFO Paul Kim noted potential revenue impacts from a key customer internalizing testing work, despite a strong cash position and plans for growth in 2026.
Read more →-FLGT
Feb 12, 2026Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics, Inc. will announce its fourth quarter and full year 2025 financial results on February 27, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 AM ET to discuss the results. The company is transitioning from diagnostics to a fully integrated precision medicine approach.
Read more →-FLGT
Dec 22, 2025Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif.—
Fulgent Genetics, Inc. has announced a definitive agreement to acquire Bako Diagnostics and StrataDx for approximately $55.5 million. This acquisition aims to enhance Fulgent's laboratory services by adding anatomic pathology and dermatopathology services, as well as proprietary PCR tests. The deal is expected to close in the first half of 2026, pending regulatory approvals. With this acquisition, Fulgent seeks to strengthen its commercial reach and expand its capabilities in the diagnostics sector, particularly through advancements in AI and digital pathology.
Read more →-FLGT
Nov 7, 2025▲ +18.2%on this news· ran to +30% by day 3
Fulgent Reports Third Quarter 2025 Financial Results
Fulgent Genetics reported a robust third quarter for 2025, achieving a revenue of $84.1 million, marking a 17% year-over-year increase. The company raised its full-year revenue guidance to $325 million and recorded a non-GAAP income of $4.5 million. Despite a GAAP loss of $6.6 million for the quarter, Fulgent emphasizes strong cash reserves of $787.7 million and expressed confidence in continued momentum in its laboratory services and therapeutic development business. Additionally, the company acknowledged ongoing efforts in clinical trials, particularly for cancer treatments.
Read more →-FLGT
Oct 20, 2025▲ +5.1%on this news
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
Fulgent Genetics announced preliminary clinical data from its Phase 2 trial investigating FID-007 combined with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, shows promising efficacy and safety profiles, with an overall objective response rate of 51%. Furthermore, the trial indicates a median progression-free survival significantly better than historical standards. The study reflects Fulgent's ambition to advance its therapeutic development capabilities.
Read more →-FLGT
Aug 1, 2025▲ +7.9%on this news· ran to +20% by day 3
Fulgent Reports Second Quarter 2025 Financial Results
Fulgent Genetics reported its financial results for the second quarter of 2025, demonstrating a 16% growth in core revenue year-over-year, amounting to $81.7 million. The company is raising its full-year core revenue guidance to $320 million, indicating strong momentum within its laboratory services business. Despite these positive aspects, Fulgent reported a GAAP loss of $19.0 million, reflecting underlying challenges. The company maintains a robust cash position of $777.5 million as it navigates forward, showing commitment to growth in its therapeutic development sector.
Read more →-FLGT
May 2, 2025▲ +19.1%on this news
Fulgent Reports First Quarter 2025 Financial Results
Fulgent Genetics, Inc. reported its financial results for the first quarter of 2025, achieving a core revenue of $73.5 million, which reflects a 16% increase year-over-year. The company reiterated its guidance for the full year, expecting a core revenue of approximately $310 million. However, it faced a GAAP loss of $11.5 million in the same quarter, highlighting continued financial pressures. Despite these losses, Fulgent maintains a significant cash position of $814.6 million and is optimistic about its growth trajectory in the laboratory services and therapeutic development sectors.
Read more →-FLGT
Feb 28, 2025Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
Fulgent Genetics, Inc. reported its fourth quarter and full year financial results for 2024, showcasing a total revenue of $283.5 million. Core revenue grew by 7% year-over-year, while the company ended 2024 with substantial cash reserves totaling $828.6 million. However, the financial results also showed a significant GAAP loss of $42.7 million for the year. Looking ahead, Fulgent expects core revenue to reach approximately $310 million in 2025 despite predicting continued GAAP losses.
Read more →-FLGT
Nov 8, 2024▼ -11.8%on this news
Fulgent Reports Third Quarter 2024 Financial Results • Total Revenue of $71.7 million • Core Revenue grows 9% year-over-year to $71.7 million • Reiterates Full Year 2024 Core Revenue Guidance of $280
Fulgent Genetics, Inc. reported third-quarter financial results for 2024, showcasing total revenues of $71.7 million, a year-over-year increase in core revenue of 9%. The company has reiterated its guidance for full-year core revenue at approximately $280 million and has improved its earnings per share forecast for 2024. Although the company experienced a GAAP loss of $14.6 million, it reported a non-GAAP income of $9.4 million. Additionally, Fulgent highlights promising early results from its Phase 2 clinical trial of FID-007 in head and neck cancer.
Read more →-FLGT
Aug 2, 2024▲ +6.3%on this news
Fulgent Reports Second Quarter 2024 Financial Results • Total Revenue of $71.0 million • Core Revenue grows 5% year-over-year to $70.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $28
Fulgent Genetics, Inc. reported its financial results for the second quarter of 2024, revealing a total revenue of $71.0 million and a core revenue growth of 5% year-over-year to $70.2 million. Although the company posted a GAAP loss of $8.7 million, it improved its non-GAAP income guidance for the year, projecting total core revenue of approximately $280 million. Fulgent continues to maintain a solid cash position of $837.9 million while advancing its therapeutic development, particularly in precision diagnostics and cancer therapies. The company's outlook remains cautiously optimistic despite reported operational losses.
Read more →About Fulgent Genetics, Inc. Common Stock
Headquarters4399 SANTA ANITA AVE, EL MONTE, CA, 91731
BIOPHARMAWATCH ELITE PLUS
Trade the next FLGT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime